Antipsychotic Polypharmacy and Metabolic Disorder Risk in Individuals With Schizophrenia

What are the cardiometabolic risks of polypharmacy with quetiapine and long-acting injectable paliperidone in patients with schizophrenia?

Related Keywords

Georgia ,United States ,United Kingdom , ,Stanley Medical Research Institute ,Augusta University ,Department Of Psychiatry ,Mental Health Services Data ,National Institute Of Mental Health ,Health Behavior At Augusta University ,United Kingdom Clinical Practice Research Datalink ,Read Codes ,Multiple Deprivation ,Health Behavior ,Editorial Board ,Psychiatric Times ,National Institute ,Mental Health ,Stanley Medical Research ,Rev Clin ,Cost Utility ,Latest Antipsychotic Drugs ,Schizophrenia Study ,March Gen ,United Kingdom Clinical Practice Research ,